InvestorsHub Logo
Followers 31
Posts 2649
Boards Moderated 0
Alias Born 10/28/2013

Re: None

Monday, 05/23/2016 4:02:35 PM

Monday, May 23, 2016 4:02:35 PM

Post# of 705558
Just watched Dr. Prins video again. I see why so many people think that the partner trials with Blockade Inhibitors will be for DCVax-L, not DCVax-Direct. He doesn't say the trials they have negotiated are with NWBO, but it is by far the most likely company that fits the description.

One thing I got out of this viewing is the likely very good efficacy for DCVax-L regarding mets.

I will watch the video many more times. I got a little more out of it viewing it on my TV, via HDMI, which has better sound than my laptop. Dr. Prins gets pretty quiet at times.

The follow-up focus on improvements beyond DCVax-L might have thrown some people. But it is clear throughout the presentation that he holds DCVax-L as being among the most promising cancer therapies, in the same class as the Blockade Inhibitors and I believe Car-T. Note that while DCVax-L is probably expensive, it is probably much cheaper than the Car-T type therapies.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News